Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colloidal oat + glycerin is a topical emollient combination used for skin barrier protection and the prevention of atopic dermatitis, particularly in high-risk infants. Colloidal oatmeal (Avena sativa) provides a complex mixture of polysaccharides, lipids, and proteins that form a protective film on the skin, while its avenanthramide components exert anti-inflammatory and antioxidant effects. Glycerin acts as a potent humectant, attracting and retaining moisture in the stratum corneum to improve skin hydration and elasticity. Clinical data from the STOP AD trial indicates that early, short-term use of this combination can modulate the infant skin microbiome, promoting the abundance of taxa associated with a lower risk of developing atopic dermatitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colloidal oat + glycerin.